ArticleProceedings of the National Academy of Sciences of the United States of America2020
Circulation of gut-preactivated naïve CD8
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- IgM promotes antitumor immunity to a Tn-expressing solid tumor.Journal for immunotherapy of cancer · 2026Article
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- A Microbial Lipid-ATP Synthase Axis Fuels NK Cell Antitumor Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Intermetallic nanoassemblies potentiate systemic STING activation.Science (New York, N.Y.) · 2026Article
- The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids.Nature communications · 2024Article
- A dynamic atlas of immunocyte migration from the gut.Science immunology · 2024Article
- Oral administration of Manuka honey induces IFNγ-dependent resistance to tumor growth that correlates with beneficial modulation of gut microbiota composition.Frontiers in immunology · 2024Article
- Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1.Nature reviews. Immunology · 2023Review
- Association of the gut microbiome with cancer immunotherapy.International journal of clinical oncology · 2023Review
- Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes.Frontiers in oncology · 2023Review
- Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy.Cancer discovery · 2022Article
- Immunoenhancing Effects ofJournal of microbiology and biotechnology · 2022Article
- The microbiome, gastrointestinal cancer, and immunotherapy.Journal of gastroenterology and hepatology · 2022Review
- Modulation of tumor environment in colorectal cancer - could gut microbiota be a key player?Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Review
- Neutrophils: Musketeers against immunotherapy.Frontiers in oncology · 2022Review
- The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.Frontiers in immunology · 2022Review
- The role of B cells in cancer development.Frontiers in oncology · 2022Review
- Article
- B cell-derived GABA elicits IL-10Nature · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome has garnered attention as an effective target to boost immunity and improve cancer immunotherapy. We found that B cell-defective (BCD) mice, such as µ-membrane targeted deletion (µMT) and activation-induced cytidine deaminase (AID) knockouts (KOs), have elevated antitumor immunity under specific pathogen-free but not germ-free conditions. Microbial dysbiosis in these BCD mice enriched the type I IFN (IFN) signature in mucosal CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.